2. PI3K/Akt/mTOR Autophagy
  3. PI3K Autophagy
  4. ZSTK474

ZSTK474 是一种 ATP 竞争性的泛 I 类 PI3K 抑制剂，抑制 PI3Kα，PI3Kβ，PI3Kδ 和 PI3Kγ，IC50 分别为 16 nM，44 nM，4.6 nM 和 49 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

ZSTK474 Chemical Structure

ZSTK474 Chemical Structure

CAS No. : 475110-96-4

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥338
In-stock
5 mg ￥308
In-stock
10 mg ￥515
In-stock
50 mg ￥1700
In-stock
100 mg ￥3100
In-stock
200 mg ￥4863
In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

Customer Review

ZSTK474 相关抗体

Top Publications Citing Use of Products

    ZSTK474 purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Jun 25;37(1):122.  [Abstract]

    MHCC97H cells are treated with either LY294002 (2.5, 5,10, 20, 40 μM) or ZSTK474 (0.5, 1, 2.5, 5, 10 μM) for 24 h. DMSO is used as the control. Cell lysates are subjected to western blot analysis with the indicated antibodies.

    查看 PI3K 亚型特异性产品:

    查看所有亚型
    PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    ZSTK474 is an ATP-competitive pan-class I PI3K inhibitor with IC50s of 16 nM, 44 nM, 4.6 nM and 49 nM for PΙ3Κα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.

    IC50 & Target[2]

    PI3Kδ

    4.6 nM (IC50)

    PI3Kα

    16 nM (IC50)

    PI3Kβ

    44 nM (IC50)

    PI3Kγ

    49 nM (IC50)

    Autophagy

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    HCT-116 IC50
    1.31 μM
    Compound: ZSTK474
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    		[PMID: 30245395]
    HCT-116 IC50
    1.31 μM
    Compound: ZSTK474
    Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay
    		[PMID: 30071408]
    HCT-116 IC50
    78 nM
    Compound: 1, ZSTK474
    Inhibition of PIK3CA H1047R mutant-mediated cell signaling in human HCT116 cells expressing PTEN assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Thr308 treated for 15 mins before insulin challenge measured after 5 mins by immunoblott
    Inhibition of PIK3CA H1047R mutant-mediated cell signaling in human HCT116 cells expressing PTEN assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Thr308 treated for 15 mins before insulin challenge measured after 5 mins by immunoblott
    		[PMID: 21882832]
    HCT-116 IC50
    97 nM
    Compound: 1, ZSTK474
    Inhibition of PIK3CA H1047R mutant-mediated cell signaling in human HCT116 cells expressing PTEN assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Ser473 treated for 15 mins before insulin challenge measured after 5 mins by immunoblott
    Inhibition of PIK3CA H1047R mutant-mediated cell signaling in human HCT116 cells expressing PTEN assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Ser473 treated for 15 mins before insulin challenge measured after 5 mins by immunoblott
    		[PMID: 21882832]
    HT-29 GI50
    300 nM
    Compound: ZSTK474
    Antiproliferative activity against human HT-29 cells incubated for 3 days by WST8 assay
    Antiproliferative activity against human HT-29 cells incubated for 3 days by WST8 assay
    		[PMID: 33284613]
    LNCaP IC50
    210 nM
    Compound: 6
    Antiproliferative activity against human LNCAP cells after 3 days by MTS assay
    Antiproliferative activity against human LNCAP cells after 3 days by MTS assay
    		[PMID: 20227881]
    MCF7 IC50
    5.27 μM
    Compound: ZSTK474
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay
    		[PMID: 30245395]
    MCF7 IC50
    5.27 μM
    Compound: ZSTK474
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay
    		[PMID: 30071408]
    MDA-MB-468 EC50
    3.2 μM
    Compound: ZSTK474
    Cytotoxicity against PTEN-deficient human MDA-MB-468 cells assessed as inhibition of cell growth after 48 hrs by Cell Titer 96 assay
    Cytotoxicity against PTEN-deficient human MDA-MB-468 cells assessed as inhibition of cell growth after 48 hrs by Cell Titer 96 assay
    		[PMID: 23795239]
    Sf21 IC50
    0.003 μM
    Compound: 4a, ZSTK474
    Inhibition of PI3Kdelta (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay
    Inhibition of PI3Kdelta (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay
    		[PMID: 23265896]
    Sf21 IC50
    0.006 μM
    Compound: 4a, ZSTK474
    Inhibition of PI3Kbeta (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay
    Inhibition of PI3Kbeta (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay
    		[PMID: 23265896]
    Sf21 IC50
    0.006 μM
    Compound: 4a, ZSTK474
    Inhibition of PI3Kalpha (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay
    Inhibition of PI3Kalpha (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay
    		[PMID: 23265896]
    Sf21 IC50
    0.038 μM
    Compound: 4a, ZSTK474
    Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay
    Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay
    		[PMID: 23265896]
    Sf21 IC50
    6 nM
    Compound: ZSTK-47
    Inhibition of PI3Kbeta (unknown origin) expressed in Escherichia coli-infected fall armyworm sf21 cells co-expressing p85 by kinase-glo luminescence assay
    Inhibition of PI3Kbeta (unknown origin) expressed in Escherichia coli-infected fall armyworm sf21 cells co-expressing p85 by kinase-glo luminescence assay
    		[PMID: 27387421]
    U-87MG ATCC IC50
    111 nM
    Compound: 1, ZSTK474
    Inhibition of PIK3CA-mediated cell signaling in PTEN-deficient human U87MG cells assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Ser473 treated for 15 mins before insulin challenge measured after 5 mins by immunoblotting
    Inhibition of PIK3CA-mediated cell signaling in PTEN-deficient human U87MG cells assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Ser473 treated for 15 mins before insulin challenge measured after 5 mins by immunoblotting
    		[PMID: 21882832]
    U-87MG ATCC IC50
    32 nM
    Compound: 1, ZSTK474
    Inhibition of PIK3CA-mediated cell signaling in PTEN-deficient human U87MG cells assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Thr308 treated for 15 mins before insulin challenge measured after 5 mins by immunoblotting
    Inhibition of PIK3CA-mediated cell signaling in PTEN-deficient human U87MG cells assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Thr308 treated for 15 mins before insulin challenge measured after 5 mins by immunoblotting
    		[PMID: 21882832]
    体外研究
    (In Vitro)

    Lineweaver-Burk plot analysis revealed that ZSTK474 inhibits all four PI3K isoforms in an ATP-competitive manner. The Ki values determined for the four PI3K isoforms showed that ZSTK474 inhibited the PI3Kδ isoform most effectively with a Ki of 1.8 nM, whereas the other isoforms are inhibited with 4-10-fold higher Ki values. Therefore, ZSTK474 should be regarded as a pan-PI3K inhibitor. We also determined the IC50 values for inhibiting the four PI3K isoforms with ZSTK474 and LY294002. The IC50 values of ZSTK474 (16, 44, 4.6 and 49 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively) are shown to be consistent with the Ki values (6.7, 10.4, 1.8 and 11.7 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively), which further supported the idea that ZSTK474 inhibits PI3Kδ most potently. Even at a concentration of 100 μM, ZSTK474 inhibits mTOR activity rather weakly[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    ZSTK474 相关抗体:
    体内研究
    (In Vivo)

    In mice subjected to MCAO, treatment with ZSTK474 is tested at dosages of 50, 100, 200, and 300 mg/kg. Since the 200 mg/kg dose produces significant improvement and no obvious toxic effects (P<0.01), mice are treated with ZSTK474 at a dose of 200 mg/kg/day daily for three post-MCAO days during the remaining experiments of this study. Neurological function is examined in mice suffered from MCAO followed by 24, 48, and 72 h of reperfusion. In the ZSTK474 group, neurological function scores are significantly better than the control group except the corner test[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    417.41

    Formula

    C19H21F2N7O2
    CAS 号
    性状

    固体

    颜色

    White to off-white

    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性数据
    细胞实验： 

    DMSO 中的溶解度 : 33.33 mg/mL (79.85 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.3957 mL 11.9786 mL 23.9573 mL
    5 mM 0.4791 mL 2.3957 mL 4.7915 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    以下溶解方案源自文献，仅供参考，建议您先取少量样品进行尝试。

    • 方案 一

      ZSTK474 is suspended in 5% hydroxypropyl cellulose[3].

    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    计算结果
    工作液所需浓度 : mg/mL
    纯度 & 产品资料

    纯度: 99.88%

    COA (296 KB) HNMR (393 KB) LCMS (94 KB)

    产品使用指南 (1538 KB)
    参考文献
    Kinase Assay
    [1]

    The linear phase of each kinetic reaction is defined at the respective enzyme amount (0.05, 0.1, 0.12 and 1 µg/mL for PI3Kα, PI3β, PI3δ and PI3γ, respectively) and reaction time (20 min). PI3K activity is assayed at various concentrations of ATP (5, 10, 25, 50, 100 µM) in the presence of increasing concentrations of ZSTK474. A Lineweaver-Burk plot is developed by plotting 1/v (the inverse of v, where v is obtained by subtracting the HTRF signal of the kinase test sample from the HTRF signal of the minus-enzyme control) versus 1/[ATP] (the inverse of the ATP concentration). For the minus-enzyme control, PIP2 is incubated with ATP in the absence of kinase. To determine the Ki value (inhibition constant) of ZSTK474 for each PI3K isoform, the slope of the respective Lineweaver-Burk plot is replotted against the ZSTK474 concentration. The Ki values are calculated by analysis using GraphPad Prism 4[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [2]

    Mice[2]
    Mice are randomly assigned to receive different doses of ZSTK474 (50, 100, 200, and 300 mg/kg) to determine the optimum dose; in our experiment, the optimum dose is 200 mg/kg. Then mice are randomly assigned to one of three groups: a sham-operated group (phosphate-buffered saline, PBS); a control group (MCAO+PBS); a ZSTK474-treated group (MCAO+ZSTK474). In the ZSTK474-treated group, the mice are given the optimum dose of 200 mg/kg ZSTK474. In the sham-operated group and control group, mice are given an equivalent volume of PBS. All mice receive that same dose daily via oral gavage beginning at 6 h after the onset of focal ischemia and continuing for two more days, i.e., for a total of 3 days.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    ZSTK474 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.3957 mL 11.9786 mL 23.9573 mL 59.8932 mL
    5 mM 0.4791 mL 2.3957 mL 4.7915 mL 11.9786 mL
    10 mM 0.2396 mL 1.1979 mL 2.3957 mL 5.9893 mL
    15 mM 0.1597 mL 0.7986 mL 1.5972 mL 3.9929 mL
    20 mM 0.1198 mL 0.5989 mL 1.1979 mL 2.9947 mL
    25 mM 0.0958 mL 0.4791 mL 0.9583 mL 2.3957 mL
    30 mM 0.0799 mL 0.3993 mL 0.7986 mL 1.9964 mL
    40 mM 0.0599 mL 0.2995 mL 0.5989 mL 1.4973 mL
    50 mM 0.0479 mL 0.2396 mL 0.4791 mL 1.1979 mL
    60 mM 0.0399 mL 0.1996 mL 0.3993 mL 0.9982 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    ZSTK474475110-96-4ZSTK 474ZSTK-474PI3KAutophagyPhosphoinositide 3-kinaseInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    ZSTK474
    目录号：
    HY-50847
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z